CDC job cuts wipe out wide array of specialists

Moves intended to refocus the agency will have severe costs to public health, critics warn.

April 1, 2025 Check out STAT+

Sponsored By

Jeff Amy/AP At CDC, Trump administration's job cuts wipe out wide array of specialists Scientists and other staff dedicated to tobacco control, injury prevention, birth defects, reproductive health, and substance abuse laid off in HHS shakeup. By Helen Branswell and Sarah Owermohle STAT+ | Ambitious NIH drive to solve brain mysteries faces uncertain future Neuroscientists said cuts could slow advances in understanding Alzheimer's when the U.S. is on track to see a doubling of new dementia cases By Jonathan Wosen and O. Rose Broderick Laid off HHS leaders offered transfers to remote Indian Health Service regions While the IHS has a longstanding vacancy rate, those openings are largely for positions such as physicians, nurses, and other care providers By Usha Lee McFarling Nardus Engelbrecht/AP Rollout of 'miracle' HIV prevention drug is threatened by Trump cuts to global AIDS relief program President's Emergency Plan for AIDS Relief had been set to lead distribution of lenacapavir, a "miracle" PrEP drug. By Ed Silverman and Jason Mast HHS starts layoffs of thousands of workers across its agencies As many as 10,000 employees — one-quarter of the department's workforce — are expected to be let go as part of the process. By Helen Branswell, Lizzy Lawrence, Sarah Owermohle, and Andrew Joseph STAT+ | The biotech scorecard for the second quarter: 24 stock-moving events to watch Plus, a new feature: We're tracking a select number of FDA-drug sponsor meetings as a potential signal of changes under the Trump administration. By Adam Feuerstein Bebeto Matthews/AP STAT+ | HHS will not enforce gender and sexual orientation requirements for medical records HHS recently said it will not enforce requirements that EHR software have fields to capture patients' sexual orientation and gender identity. By Katie Palmer STAT+ | Trump's proposed tariffs may cause shortages of Canadian-made drugs in the U.S., analysis finds The looming threat of tariffs has the pharmaceutical industry, investors and consumer groups on edge and calculating the implications. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser